KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Treasury Shares (2016 - 2025)

Emergent BioSolutions' Treasury Shares history spans 14 years, with the latest figure at $252.6 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 10.94% year-over-year to $252.6 million; the TTM value through Dec 2025 reached $252.6 million, up 10.94%, while the annual FY2025 figure was $252.6 million, 10.94% up from the prior year.
  • Treasury Shares reached $8.7 million in Q4 2025 per EBS's latest filing, up from $7.9 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $8.7 million in Q4 2025 to a low of $1.2 million in Q1 2021.
  • Average Treasury Shares over 5 years is $5.1 million, with a median of $5.6 million recorded in 2022.
  • Peak YoY movement for Treasury Shares: changed 0.0% in 2021, then skyrocketed 475.0% in 2022.
  • A 5-year view of Treasury Shares shows it stood at $152.2 million in 2021, then surged by 49.61% to $227.7 million in 2022, then changed by 0.0% to $227.7 million in 2023, then changed by 0.0% to $227.7 million in 2024, then rose by 10.94% to $252.6 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Treasury Shares are $252.6 million (Q4 2025), $243.5 million (Q3 2025), and $234.6 million (Q2 2025).